The restructuring that Hoechst Marion Roussel has been undertaking over the last two years is apparently paying off with the company's second quarter net profit more than doubling despite a 5.8% decline in the topline. The decline in the topline is partly on account of the sale of two brands Omnatax and Haemaccel to Nicholas Piramal last year.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
Earnings per share*
Over the last two years the company has sold off two of its plants based in Mumbai and written off a huge amount in VRS expenditure. Meanwhile it has introduced nine new products from its parent's stable. While the revenue from these products will show up in the revenue growth in the future, the repayment of debt using the cash accrued from the sale of its assets has helped the company reduce interest costs.
Almost 60% of the company's revenues accrues from products under price control. These include well known brands such as Combiflam (cough and colds), Daonil (anti–diabetics) and Soframycin (dermatology).
The stock quotes at Rs 453 which implies an earnings multiple of 21 times FY01 annualised earnings. The results are in line with our expectations. Overall, for the first half the company has reported a net profit of Rs 200 m while we had projected a net profit of Rs 370 m for the full year FY01.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407